Mereo BioPharma Group (MREO) Expected to Announce Earnings on Monday

Mereo BioPharma Group (NASDAQ:MREO) is projected to release its Q3 2026 resultson Monday, November 9th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $4.61 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 2:00 AM ET.

Mereo BioPharma Group (NASDAQ:MREO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). On average, analysts expect Mereo BioPharma Group to post ($0.04) EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Mereo BioPharma Group Stock Performance

Shares of MREO opened at $0.29 on Monday. The stock has a 50 day moving average price of $0.31 and a 200 day moving average price of $0.34. Mereo BioPharma Group has a one year low of $0.20 and a one year high of $2.37. The stock has a market capitalization of $46.23 million, a price-to-earnings ratio of -7.24 and a beta of 0.29.

Analyst Ratings Changes

A number of brokerages have recently commented on MREO. JPMorgan Chase & Co. cut shares of Mereo BioPharma Group from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 19th. BTIG Research restated a “buy” rating and set a $1.00 target price on shares of Mereo BioPharma Group in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Mereo BioPharma Group in a research report on Tuesday, September 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Mereo BioPharma Group in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1.67.

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and oncology. The company’s research programs are intended to address conditions with significant unmet medical needs, using biologic and small-molecule drug candidates.

Mereo’s lead program is setrusumab, an investigational monoclonal antibody designed to inhibit sclerostin and stimulate bone formation. The therapy is being developed for osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones, through a collaboration with Ultragenyx Pharmaceutical.